Inspired by a genetic mutation that keeps low-density lipoprotein levels extremely low, three pharmaceutical companies are developing cholesterol drugs that mimic the trait. The New York Times described how drug makers are scurrying to get these potential blockbusters to market.

Amgen and Servier today announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease.

The Charles & Barbara Duboc Cardio Health & Wellness Center is ushering in a new era for preventive cardiac care at Saint Luke's Hospital..

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended the anticoagulant rivaroxaban as a possible treatment for adults with pulmonary embolism and to prevent recurrent deep vein thrombosis or pulmonary embolism.

The June issue of Pharmaceuticals Monthly explores the delay in the approval of apixaban (Eliquis) by the FDA. “Apixaban shows how a review that seems, on its face, like it should be a quick and clean affair can become derailed by issues that, but for the agency’s own public disclosures post-approval, would never see the light of day,” according to the article.

A new $11 million grant to Kaiser Permanente Northern California and UC San Francisco will support a multifaceted research program aimed at lowering stroke risk among black populations and younger stroke victims by targeting high blood pressure, also known as hypertension.

A promising bipartisan bill that increases vital access and reimbursement for obesity screening and counseling services has been introduced in Congress, thanks in part to the Academy of Nutrition and Dietetics.